Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease

cT1 (LiverMultiScan) was significantly reduced after 16 weeks of novel NASH treatment, AXA1125, versus placebo, with twice as many patients achieving a reduction of cT1 ≥ 80 ms, previously linked to improved histopathological outcomes. AXA1125 also reduced liver fat (MRI-PDFF) and improved metabolic and fibro-inflammatory markers (HOMA-IR, ALT, CK18-M65, Pro-C3).